<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139360">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01655082</url>
  </required_header>
  <id_info>
    <org_study_id>V00116 TD 2 02</org_study_id>
    <secondary_id>2011-005911-94</secondary_id>
    <nct_id>NCT01655082</nct_id>
  </id_info>
  <brief_title>Nicotine Patch Safety Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Medicament</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pierre Fabre Medicament</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: Comité de Protection des Personnes</authority>
    <authority>France: Conseil National de l'Ordre des Médecins</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety profile of  a repeated application of a
      new transdermal patch compared to a reference product during 3 weeks, in a large population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>up to Day 22</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluation of local safety (number of subjects with skin irritation / number of subjects by score of adhesiveness) and general safety (number of subjects with emergent adverse events or changes from baseline to end of study in vital signs, electrocardiogram  and clinical laboratory parameters).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensory profile</measure>
    <time_frame>Day 22</time_frame>
    <safety_issue>No</safety_issue>
    <description>Visual Analogic Scales (sensations linked to patch application and removal)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment by the patient</measure>
    <time_frame>Day 22</time_frame>
    <safety_issue>No</safety_issue>
    <description>Visual Analog Scale Scale and questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject behaviours</measure>
    <time_frame>up to Day 22</time_frame>
    <safety_issue>No</safety_issue>
    <description>nicotine consumption</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Smokers</condition>
  <arm_group>
    <arm_group_label>V0116</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One patch per day (during 24 hours) for 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One patch per day (during 24 hours) for 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>V0116 transdermal patch</intervention_name>
    <description>One patch per day (during 24 hours) for 21 days</description>
    <arm_group_label>V0116</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine transdermal patch</intervention_name>
    <description>One patch per day (during 24 hours) for 21 days</description>
    <arm_group_label>Reference</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female  aged more than 18 years

          -  Regular smoker motivated to stop tobacco consumption

          -  Current smoker of &gt; or = 20 cigarettes/day and &lt; or = 25 cigarettes/day or Fagerström
             score &gt; or = 5 (for smokers between 10 to 20 cigarettes/day)

        Exclusion Criteria:

          -  Any visible skin disorder, abnormal skin pigmentation or other dermatologic disease
             which, in the opinion of the investigator would interfere with the assessment of the
             different parameters

          -  Current or past serious chronic cardiovascular, renal, hepatic, gastrointestinal
             (including duodenal or gastric ulcer), endocrine, hematological, neuropsychiatric,
             immunosuppressive condition or allergic disease, myopathies, epileptic seizures,
             bleeding tendency, cancer

          -  History of angina pectoris, myocardial infarction or stroke in the previous 3 months,
             coronary artery vasospasm, cardiac arrhythmia, acute stroke

          -  Clinically relevant abnormal findings on the physical examination (e.g large scars on
             the application zone)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Gières</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pierre - Benite</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rueil - Malmaison</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 10, 2012</lastchanged_date>
  <firstreceived_date>July 30, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking cessation</keyword>
  <keyword>Nicotine</keyword>
  <keyword>Tobacco Use Disorder</keyword>
  <keyword>Central Nervous System Agents</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Central Nervous System Agents</mesh_term>
    <mesh_term>Nicotine polacrilex</mesh_term>
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
